PEOPLE - SELECT Therapeutics makes appointment:
This article was originally published in Clinica
The chairman of SELECT Therapeutics has announced the appointment of Andrew Muir as CEO and director. Dr Muir possesses over 30 years of management experience and is a member of the board of directors for several private technology companies. The vice-chairman of the board has been named as Thomas Reardon, who has been with the company since 1999. Steve Peltzman has resigned as CEO.
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.